Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Middle Peak Medical: US Mitral Valve Start-Up Goes To Europe For Funding

Executive Summary

You know times are tough for medtech start-ups in the US when even a successful serial entrepreneur like Michael Lesh, MD, is told by VCs, “We love your idea, but….” Middle Peak Medical, Lesh’s new start-up in the mitral valve space, solved its problem with a Series A financing round involving European investors and by co-locating itself in Germany and the US.

You may also be interested in...

TAVR Competitors Put Pressure On Edwards To Deliver On New Growth Drivers

Edwards is betting on next-generation Sapien devices and efforts towards a transcatheter mitral valve, as Medtronic and other competitors move closer to threatening the firm’s TAVR leadership position.

Device Investors Showing Some Spine

Elsevier’s Strategic Transactions shows that just in the last year, 26 spine or low back pain companies received private funding. To be sure, many were small rounds, some were funded with debt, and some were insider rounds trying to keep companies moving forward, but venture investors showed excitement by investing in large rounds for a select number of start-ups.

FDA Advisors Vote That Benefits Of Abbott’s MitraClip Outweigh Risks

The agency’s Circulatory System Devices Panel narrowly voted in favor of Abbott’s MitraClip transcatheter mitral valve repair system to reduce mitral regurgitation. But the discussions about the clinical evidence on the technology were complex and the panel’s support for Abbott’s PMA was not unanimous.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts